These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6821084)

  • 21. Chemoprophylaxis for Neisseria meningitidis in an isolated Arctic community.
    Nicolle LE; Postl B; Kotelewetz E; Remillard F; Bourgault AM; Albritton W; Harding GK; Ronald A
    J Infect Dis; 1982 Jan; 145(1):103-9. PubMed ID: 6798128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nasopharyngeal carriage of Neisseria meningitidis in general population and meningococcal disease.
    Ichhpujani RL; Mohan R; Grover SS; Joshi PR; Kumari S
    J Commun Dis; 1990 Dec; 22(4):264-8. PubMed ID: 2129123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Occurence, prevention and therapy of meningococcic meningitis].
    Berger U
    Med Klin; 1975 Oct; 70(41):1628-35. PubMed ID: 810651
    [No Abstract]   [Full Text] [Related]  

  • 24. [Persistence and transmission of Neisseria meningitidis in a family with a case of fatal infection].
    Sáez Nieto JA; Marín M; Casanovas A; Marcos C
    Enferm Infecc Microbiol Clin; 1990 Apr; 8(4):222-4. PubMed ID: 2128608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nasopharyngeal carriage of Neisseria meningitidis in the contacts of index cases of meningococcal meningitis.
    Ichhpujani RL; Singh T; Kumari S; Basu RN
    J Commun Dis; 1986 Mar; 18(1):1-5. PubMed ID: 3091676
    [No Abstract]   [Full Text] [Related]  

  • 26. In-vitro and in-vivo studies of resistance to rifampin in meningococci.
    Eickhoff TC
    J Infect Dis; 1971 Apr; 123(4):414-20. PubMed ID: 4999905
    [No Abstract]   [Full Text] [Related]  

  • 27. The chemoprophylaxis of cerebrospinal meningitis using rifampin in a military population.
    Chapalain JC; Guibourdenche M; Perrier-Gros-Claude JD; Bartoli M; Riou JY
    Pathol Biol (Paris); 1992 Mar; 40(3):230-3. PubMed ID: 1608666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemoprophylaxis of meningococcal carriers.
    Artenstein MS
    N Engl J Med; 1969 Sep; 281(12):678. PubMed ID: 4980026
    [No Abstract]   [Full Text] [Related]  

  • 29. Evaluation of the use of mass chemoprophylaxis during a school outbreak of enzyme type 5 serogroup B meningococcal disease.
    Jackson LA; Alexander ER; DeBolt CA; Swenson PD; Boase J; McDowell MG; Reeves MW; Wenger JD
    Pediatr Infect Dis J; 1996 Nov; 15(11):992-8. PubMed ID: 8933547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of rifampin on the nasopharyngeal carriage of Neisseria meningitidis in a military population.
    Beam WE; Newberg NR; Devine LF; Pierce WE; Davies JA
    J Infect Dis; 1971 Jul; 124(1):39-46. PubMed ID: 5004115
    [No Abstract]   [Full Text] [Related]  

  • 31. [Prevention of meningococcal meningitis].
    Helwig H
    Dtsch Med Wochenschr; 1981 Jan; 106(1):25-7. PubMed ID: 7004828
    [No Abstract]   [Full Text] [Related]  

  • 32. Control of group C meningococcal disease in Australian aboriginal children by mass rifampicin chemoprophylaxis and vaccination.
    Pearce MC; Sheridan JW; Jones DM; Lawrence GW; Murphy DM; Masutti B; McCosker C; Douglas V; George D; O'Keefe A
    Lancet; 1995 Jul; 346(8966):20-3. PubMed ID: 7603139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rifampicin and erythromycin for the meningococcal carrier.
    Wall RA; Gruneberg RN
    Lancet; 1982 Dec; 2(8311):1346. PubMed ID: 6128633
    [No Abstract]   [Full Text] [Related]  

  • 34. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region.
    Soriano-Gabarró M; Wolter J; Hogea C; Vyse A
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):761-74. PubMed ID: 21905785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of a rifampicin-resistant meningococcal infection in a teenager.
    Delaune D; Andriamanantena D; Mérens A; Viant E; Aoun O; Ceppa F; Taha MK; Rapp C
    Infection; 2013 Jun; 41(3):705-8. PubMed ID: 23408002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does eradication of meningococcal carriage in household contacts prevent secondary cases of meningococcal disease?
    Stuart JM; Cartwright KA; Robinson PM; Noah ND
    BMJ; 1989 Mar; 298(6673):569-70. PubMed ID: 2495116
    [No Abstract]   [Full Text] [Related]  

  • 37. The Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine.
    MenAfriCar consortium
    J Infect Dis; 2015 Oct; 212(8):1298-307. PubMed ID: 25858956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preventing secondary cases of meningococcal disease by identifying and eradicating disease-causing strains in close contacts of patients.
    Kristiansen BE; Tveten Y; Ask E; Reiten T; Knapskog AB; Steen-Johnsen J; Hopen G
    Scand J Infect Dis; 1992; 24(2):165-73. PubMed ID: 1641593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrafamilial meningococcal meningitis.
    Naveh Y; Merzbach D
    Eur J Pediatr; 1980 Sep; 134(3):265-7. PubMed ID: 7428775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of sulfadiazine in the prophylaxis of group A meningococcal carriers in Egypt.
    Hassan A; Girgis N; Sippel J; Sorensen K; Yassin M
    Trop Geogr Med; 1974 Mar; 26(1):87-90. PubMed ID: 4208558
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.